Editing Von Hippel–Lindau disease (section)

==Treatment==
Early recognition and treatment of specific manifestations of VHL can substantially decrease complications and improve quality of life. For this reason, individuals with VHL disease are usually screened routinely for retinal angiomas, CNS hemangioblastomas, clear-cell renal carcinomas and pheochromocytomas.<ref>{{cite journal |author=Priesemann M |author2=Davies KM |author3=Perry LA |display-authors=etal |year=2006 |title=Benefits of screening in von Hippel-Lindau disease – comparison of morbidity associated with initial tumours in affected parents and children |journal=[[Horm. Res.]] |volume=66 |issue=1 |pages=1–5 |doi=10.1159/000093008 |pmid=16651847|s2cid=29862078 }}</ref> CNS hemangioblastomas are usually surgically removed if they are symptomatic. [[Photocoagulation]] and [[cryotherapy]] are usually used for the treatment of symptomatic retinal angiomas, although anti-angiogenic treatments may also be an option. Renal tumours may be removed by a partial [[nephrectomy]] or other techniques such as [[radiofrequency ablation]].<ref name="pmid21386872" />

[[Belzutifan]] is a drug under investigation for the treatment of von Hippel–Lindau disease-associated [[renal cell carcinoma]].<ref>{{cite web | title=Belzutifan | website=SPS - Specialist Pharmacy Service | date=18 March 2021 | url=https://www.sps.nhs.uk/medicines/belzutifan/ | access-date=25 April 2021 | archive-date=26 April 2021 | archive-url=https://web.archive.org/web/20210426052135/https://www.sps.nhs.uk/medicines/belzutifan/ | url-status=dead }}</ref><ref name="raps">{{cite press release | title=MHRA awards first 'innovation passport' under new pathway | website=RAPS | url=https://www.raps.org/news-and-articles/news-articles/2021/2/mhra-awards-first-innovation-passport-under-new-pa | access-date=25 April 2021}}</ref><ref>{{cite press release | title=Merck Receives Priority Review From FDA for New Drug Application for HIF-2α Inhibitor Belzutifan (MK-6482) | publisher=Merck | via=Business Wire | date=16 March 2016 | url=https://www.businesswire.com/news/home/20210316005293/en/ | access-date=25 April 2021}}</ref><ref>{{Cite web|title=FDA Grants Priority Review to Belzutifan for von Hippel-Lindau Disease–Associated RCC|url=https://www.cancernetwork.com/view/fda-grants-priority-review-to-belzutifan-for-von-hippel-lindau-disease-associated-rcc|access-date=2021-04-26|website=Cancer Network|date=16 March 2021 }}</ref>